Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Inhibrx Biosciences to related businesses based on the strength of its dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Inhibrx Biosciences and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
| Inhibrx Biosciences Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
Inhibrx Biosciences presently has a consensus price target of $185.00, indicating a potential upside of 168.23%. As a group, “Biotechnology” companies have a potential upside of 114.44%. Given Inhibrx Biosciences’ higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than its rivals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx Biosciences | N/A | -563.90% | -80.38% |
| Inhibrx Biosciences Competitors | -12,224.75% | -204.85% | -31.52% |
Risk and Volatility
Inhibrx Biosciences has a beta of 4.03, indicating that its stock price is 303% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences’ rivals have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.
Valuation and Earnings
This table compares Inhibrx Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Inhibrx Biosciences | $1.30 million | -$140.05 million | -7.61 |
| Inhibrx Biosciences Competitors | $688.58 million | $7.69 million | -17.98 |
Inhibrx Biosciences’ rivals have higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Inhibrx Biosciences beats its rivals on 7 of the 13 factors compared.
Inhibrx Biosciences Company Profile
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
